Online inquiry

IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ658MR)

This product GTTS-WQ658MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AOC3 gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001277731.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8639
UniProt ID Q16853
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ658MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14674MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ10277MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ9630MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7278MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ3395MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ13627MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ7183MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ11784MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW